Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab + autologous NK cells
- Development stage
- Unknown
- Lead developer
- Xuzhou Medical University
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
This investigational cellular immunotherapy consists of activated and expanded autologous natural killer (NK) cells administered in combination with the HER2-targeted monoclonal antibody trastuzumab. Developed by Xuzhou Medical University, the therapy involves collecting a patient's own NK cells via apheresis and expanding them ex vivo using a K562 feeder cell line genetically modified to express membrane-bound interleukin-15 (IL-15) and 4-1BB ligand (4-1BBL). The treatment regimen typically includes trastuzumab to target HER2-positive cancer cells and subcutaneous interleukin-2 (IL-2) to support NK cell survival and activity. The primary mechanism of action is the enhancement of antibody-dependent cellular cytotoxicity (ADCC), where the expanded NK cells recognize and destroy trastuzumab-coated tumor cells, specifically for the treatment of HER2-positive advanced gastric cancer.
- Other names
- activated and expanded autologous NK cellsexpanded NK cellsCombination Trastuzumab With Expanded NK Cells
02
Targets
FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on trastuzumab + autologous NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab + autologous NK cells.